Investor List:

Top Therapeutics Series B Investors (98)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Therapeutics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in Manufacturing (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Manufacturing (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Manufacturing (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Manufacturing (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Manufacturing (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Los Angeles / Southern California (Other Lists), Investors in Boston / New England (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Scott Biller, Venture Partner at GV (Google Ventures)
Scott Biller
GV (Google Ventures)·Venture Partner
Sweet spot: $25.0M
Range: $250K - $50.0M
Investors in Boston (MA)
Photo of Aiden Aceves, Vice President at Insight Partners
Aiden Aceves
Insight Partners·Vice President
Sweet spot: $25.0M
Range: $10.0M - $350.0M
Investors in San Diego (CA)
Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in AI (Series A), Investors in BioTech (Series A), Investors in AI (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in BioTech (Series B), Investors in AI (Series B), Investors in BioTech (Series B), Investors in AI (Series B), Investors in Los Angeles / Southern California (Other Lists)
Photo of James C. Murray, Partner at ExSight Capital Management
James C. Murray
Sweet spot: $1M
Range: $200K - $4.0M
Investors in Europe, Investors in Canada, Investors in United States
Investors in Pharmaceuticals (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Drug Delivery (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Robotics (Pre-seed), Investors in Hardware (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Drug Delivery (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Hardware (Pre-seed), Investors in Robotics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Seed), Investors in Medical Devices (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Drug Delivery (Seed), Investors in Digital Health (Seed), Investors in Diagnostics (Seed), Investors in Health & Hospital Services (Seed), Investors in Hardware (Seed), Investors in Therapeutics (Seed), Investors in Robotics (Seed), Investors in Drug Delivery (Seed), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Hardware (Seed), Investors in Robotics (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Therapeutics (Series A), Investors in Drug Delivery (Series A), Investors in Hardware (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Diagnostics (Series A), Investors in Digital Health (Series A), Investors in Diagnostics (Series A), Investors in Health & Hospital Services (Series A), Investors in Robotics (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in Drug Delivery (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Hardware (Series A), Investors in Robotics (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Series B), Investors in Hardware (Series B), Investors in Drug Delivery (Series B), Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Series B), Investors in Therapeutics (Series B), Investors in Health & Hospital Services (Series B), Investors in Diagnostics (Series B), Investors in BioTech (Series B), Investors in Robotics (Series B), Investors in Therapeutics (Series B), Investors in Drug Delivery (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Hardware (Series B), Investors in Robotics (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Canada (Other Lists), Investors in Investors who were founders (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in New York City (Other Lists)
Photo of Adam Fried, Managing Partner at Friedom Partners
Adam Fried
Friedom Partners·Managing Partner
Sweet spot: $10.0M
Range: $3.0M - $30.0M
Investors in United States
Photo of Xinhong Lim, Managing Director at Vickers Venture Partners
Xinhong Lim
Vickers Venture Partners·Managing Director
Sweet spot: $5.0M
Range: $3.0M - $10.0M
Investors in Singapore, Investors in United Kingdom, Investors in United States, Investors in China, Investors in Indonesia, Investors in Canada
Investors in Semiconductors (Series A), Investors in Chemicals (Series A), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Material Science (Series A), Investors in Medical Devices (Series A), Investors in Therapeutics (Series A), Investors in EnergyTech (Series A), Investors in BioTech (Series A), Investors in ClimateTech/CleanTech (Series A), Investors in Chemicals (Series A), Investors in AI (Series A), Investors in Material Science (Series A), Investors in Semiconductors (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in EnergyTech (Series A), Investors in ClimateTech/CleanTech (Series A), Investors in BioTech (Series A), Investors in AI (Series A), Investors in Chemicals (Series B), Investors in Semiconductors (Series B), Investors in Material Science (Series B), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Series B), Investors in EnergyTech (Series B), Investors in Therapeutics (Series B), Investors in BioTech (Series B), Investors in Chemicals (Series B), Investors in ClimateTech/CleanTech (Series B), Investors in AI (Series B), Investors in Material Science (Series B), Investors in Semiconductors (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in EnergyTech (Series B), Investors in ClimateTech/CleanTech (Series B), Investors in BioTech (Series B), Investors in AI (Series B), Investors in Canada (Other Lists), Investors in Diverse Investors (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Wes Schifone, Scout at CRV
Wes Schifone
CRV·Scout
Sweet spot: $50K
Range: $25K - $100K
Investors in Boston (MA)
Investors in Therapeutics (Seed), Investors in Wellness & Fitness (Seed), Investors in Therapeutics (Seed), Investors in Web3/Blockchain (Seed), Investors in Consumer Health (Seed), Investors in Digital Health (Seed), Investors in Wellness & Fitness (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Web3/Crypto (Seed), Investors in Consumer Health (Seed), Investors in Digital Health (Seed), Investors in Web3/Blockchain (Seed), Investors in Health & Hospital Services (Seed), Investors in Web3/Crypto (Seed), Investors in Health IT (Seed), Investors in Therapeutics (Series A), Investors in Wellness & Fitness (Series A), Investors in Therapeutics (Series A), Investors in Web3/Blockchain (Series A), Investors in Consumer Health (Series A), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in Wellness & Fitness (Series A), Investors in Health IT (Series A), Investors in Web3/Crypto (Series A), Investors in Consumer Health (Series A), Investors in Digital Health (Series A), Investors in Web3/Blockchain (Series A), Investors in Web3/Crypto (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Therapeutics (Series B), Investors in Wellness & Fitness (Series B), Investors in Therapeutics (Series B), Investors in Web3/Blockchain (Series B), Investors in Consumer Health (Series B), Investors in Wellness & Fitness (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Consumer Health (Series B), Investors in Web3/Crypto (Series B), Investors in Web3/Blockchain (Series B), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Web3/Crypto (Series B), Investors in Boston / New England (Other Lists), Investors in Angel, Scout, and Solo-Capitalists (Other Lists)
Photo of Pablo Lubroth, Investor at Hummingbird Ventures
Pablo Lubroth
Sweet spot: $2.8M
Range: $500K - $5.0M
Investors in London, Investors in New York (NY)
Investors in Therapeutics (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in DeepTech (Pre-seed), Investors in BioTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in DeepTech (Seed), Investors in Digital Health (Seed), Investors in Therapeutics (Seed), Investors in DeepTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in DeepTech (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Therapeutics (Series A), Investors in DeepTech (Series A), Investors in Therapeutics (Series A), Investors in Digital Health (Series A), Investors in DeepTech (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Pharmaceuticals (Series A), Investors in DeepTech (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series B), Investors in DeepTech (Series B), Investors in Therapeutics (Series B), Investors in DeepTech (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Pharmaceuticals (Series B), Investors in DeepTech (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in London (Other Lists), Investors in New York City (Other Lists)